Figure 7. Gp120 enhancement of EPSC_NR2AR and EPSC_NR2BR.

A. EPSC_NR2AR was isolated by addition of AMPAR antagonist CNQX (10μM) and NR2BR antagonist ifenprodil (10μM) to the perfusate. Exemplary EPSC_NR2AR traces were recorded in a CA1 neuronal cell before (Ctrl), during (gp120), after (washout) bath perfusion of gp120, and subsequent pharmacological confirmation of EPSC_NR2AR by a specific NR2AR blocker R-CPP (CPP). Note that bath perfusion of gp120 increased EPSC_NR2A and the EPSC_NR2A returned to control level after washout of gp120. Addition of R-CPP almost completely blocked EPSC_NR2A, demonstrating the pharmacologically isolated EPSCs were EPSC_NR2AR. B. EPSC_NR2BR was isolated with the addition of AMPAR antagonist CNQX (10μM) and NR2AR antagonist R-CPP (1μM) to the perfusate. Exemplary EPSC_NR2BR traces were recorded from another CA1 neuronal cell before (Ctrl), during (gp120), after (washout) bath perfusion of gp120, and pharmacological confirmation of EPSC_NR2BR by a specific NR2BR blocker ifenprodil (Ifenprodil). B and D are summary bar graphs showing average amplitudes (% of control) of EPSCnr₂ar (B) and EPSC_NR2BR (D) recorded under various experimental conditions as indicated, respectively. Note that gp120 enhanced both EPSC_NR2AR (128.61±18.64% of control, n=11, M±SD) and EPSC_NR2BR (159.25±22.77% of control, n=8, M±SD) with a significant stronger effect (t₍₁₇₎=0.0046; p<0.01) on enhancing EPSC_NR2BR and EPSC_NR2AR. * p<0.05 vs control; # p<0.05 vs gp120 group.